Skip to content

Clinical efficacy and safety of doxycycline combined with probiotics in the treatment of rosacea: a multicenter, randomized, controlled, double-blind clinical trial

Clinical efficacy and safety of doxycycline combined with probiotics in the treatment of rosacea: a multicenter, randomized, controlled, double-blind clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073060
Enrollment
Unknown
Registered
2023-06-30
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Interventions

Doxycycline combined with A probiotics group:Oral Doxycycline 0.05 g Qd for 8 weeks and probiotics A 2 packs Qd for 16 weeks.
Doxycycline combined with B probiotics group:Oral Doxycycline 0.05 g Qd for 8 weeks and probiotics B 2 packs Qd for 16 weeks.
Doxycycline combined with probiotics mimetic group:Oral Doxycycline 0.05 g Qd for 8 weeks and probiotics mimetic 2 packs Qd for 16 weeks.

Sponsors

Xiangya Hospital Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with rosacea (characterized by persistent erythema or pustular papule as the predominant phenotype) and those with voluntary informed consent.

Exclusion criteria

Exclusion criteria: Participants who met one of the following criteria were excluded from the trial: (1) age 65 years old; (2) pregnant and lactating women and those who have a recent pregnancy plan; (3) patients with diabetes mellitus, moderate or severe liver, kidney, lung or blood diseases; (4) patients with depression or mental disorders; (5) The facial manifestations of rosacea patients with the main clinical manifestations of hyperplasia and hypertrophy, or with other facial skin diseases (such as seborrheic dermatitis, eczema, etc.) or other systemic diseases (such as dermatomyositis, systemic lupus erythematosus) ; (6) participants in any clinical trial within one month; (7) use of probiotics (supplements or food enhancers) or oral antibiotics within 1 month before the start of the study; (8) patients who received any other form of rosacea treatment 1 month before the start of the study; (9) Allergic to probiotics or doxycycline; (10) other conditions that the researchers considered unacceptable.

Design outcomes

Primary

MeasureTime frame
Rosacea Clinical Symptom Severity Assessment (Physician Assessment);Rosacea Clinical Symptom Severity Assessment (Patient Assessment);

Secondary

MeasureTime frame
Skin Life Quality Index (DLQI) Questionnaire;Facial clinical photos and VISIA photos of patients with rosacea;Helicobacter pylori test, methane hydrogen test, intestinal microbiology test;

Countries

China

Contacts

Public ContactBen Wang

Dermatology Hospital of Central South University Xiangya Hospital

wangben0804@163.com+86 138 7588 5737

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026